Series 1 (KLS-116 & analogues)
Complicated and difficult-to-treat bacterial infections
Pre-clinicalActive
Key Facts
Indication
Complicated and difficult-to-treat bacterial infections
Phase
Pre-clinical
Status
Active
Company
About Metallobio
MetalloBio is a private, preclinical-stage biotech tackling the global AMR crisis with a novel class of inorganic, metal-core-based antimicrobials. Its lead program, KLS-116, is a fast-acting bactericide with multiple killing mechanisms and minimal resistance development. The company is currently fundraising to advance its candidate selection and mechanistic studies, aiming to progress its most promising compounds into clinical trials.
View full company profile